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Health professional feedback on HPV 1 
vaccination roll-out in a developing country 2 
 3 
ABSTRACT 4 
 5 
Background: Worldwide, Zambia has the highest cervical cancer incidence rates 6 
(58.4/100,000 per year) and mortality rates (36.2/100,000 per year). The human papilloma 7 
virus (HPV) vaccine is considered a vital preventative measure against cervical cancer, 8 
particularly in sub-Saharan countries, such as Zambia. Past research suggests health 9 
professionals’ experiences with HPV vaccination rollout can have practical implications for 10 
effective delivery.  11 
 12 
Objective: To explore health professionals’ perspectives on the HPV vaccination programme 13 
in Zambia. 14 
 15 
Methods: Researcher travelled to Zambia and conducted semi-structured interviews with 16 
fifteen health professionals working in private, government, and missionary clinics/hospitals. 17 
Observation was conducted for triangulation purposes. Thematic analysis was used to analyse 18 
the data. 19 
 20 
Findings: Five main themes emerged; medical misconceptions about the HPV vaccination, 21 
particularly with regards to infertility; fear of the unknown, including possible side effects 22 
and inadequate empirical research; need for prior desensitisation to resolve cultural barriers 23 
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prior to vaccination rollout; a rural-urban divide in health awareness, particularly in relation 24 
to cancer vaccines; and economic concerns associated with access to the HPV vaccination for 25 
most of the Zambian population. 26 
 27 
Conclusion: Overall, the findings indicate that an essential avenue for facilitating HPV 28 
vaccination rollout in Zambia is by implementing a pre-rollout community effort that 29 
removes or softens cultural barriers, particularly in rural areas. It is also essential to correct 30 
erroneous HPV presumptions health professionals may have around infertility. Affordability 31 
remains a seemingly intractable hindrance that hampers HPV vaccination rollout in Zambia. 32 
 33 
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INTRODUCTION 36 
Cervical cancer is a major global health problem, rated as the third most common cancer in 37 
women [1]. Around 85% of cases occur in developing countries [2, 3]. Zambia in particular 38 
has the highest cervical cancer incidence rates (58.4/100,000 per year) and mortality rates 39 
(36.2/100,000 per year) worldwide [4]. Today, cervical cancer is the first cause of female 40 
cancer in Zambia, and the most common female cancer in women aged 15 to 44 years in this 41 
country [5]. Tackling cervical cancer in sub-Saharan countries is difficult, partly because 42 
multiple and complex socio-cultural factors contribute to its high mortality rates in these 43 
geographical regions [6]. 44 
HPV (human papilloma virus) infection is extremely detrimental for women in 45 
countries like Zambia, where the known adult HIV prevalence rate is 16% [7]. HIV and 46 
cervical cancer rates are strongly correlated [3]. HPV infection can double a woman’s risk of 47 
acquiring HIV as it causes lesions in the cervix and vagina, which act as transmission sites 48 
3 
 
for the virus [8]. Not only are HIV positive women more likely to develop cervical cancer, 49 
but once contracted, cervical cancer develops even faster in HIV positive women [8]. 50 
Although systematic cervical cytology screening programmes are considered an essential tool 51 
for addressing cervical cancer in developing countries, research suggests these schemes aren’t 52 
necessarily feasible in some developing countries [9]. One systematic review suggests lack of 53 
resources faced by less economically developed countries, like Zambia, limits women’s 54 
access to both treatment and screening services, possibly contributing to the high prevalence 55 
of cervical cancer in such countries [3]. Knowledge of HPV is poor in many developing 56 
regions. For example, a study of 500 women in Sudan found that only 39.2% had heard about 57 
the HPV vaccination [10]. A similar investigation in Lebanon reported a knowledge score of 58 
just 52.7%, suggesting limited awareness of the vaccine [11]. However, knowledge of HPV 59 
appears to be relatively high in Zambia, with one study suggesting 74.7% of adult women 60 
have heard about cervical cancer, and 73.3% consider it preventable [12].  61 
 62 
Pilot HPV vaccination programme in Zambia 63 
The HPV vaccine was one of four new vaccines planned to be introduced into the routine 64 
immunization system in Zambia (the others comprising the rotavirus vaccine, pneumococcal, 65 
and the second dose of measles) [13]. However it has only been introduced on a pilot basis in 66 
three districts in the Lusaka province [14]. On 27 May 2013, the pilot scheme was launched, 67 
targeting schoolgirls (aged 9 to 13) in grade four. During the initial phase (2013 to 2014) 68 
approximately 50,000 girls were targeted [15]. Girls out of school were meant to receive the 69 
vaccine through outreach strategies and health centres [15]. Over the course of the pilot 70 
programme, from 2013 to 2014, an estimated 33,733 young girls were vaccinated with the 71 
full three doses [16]. The international organization Pink Ribbon Red Ribbon is donating an 72 
extra 30,000 vaccines [16]. As the HPV vaccine is one of the most expensive recommended 73 
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inoculations, its success is pivoted upon its affordability in limited resource settings [17]. The 74 
Global Alliance for Vaccines and Immunisation (GAVI) have taken steps to increase 75 
affordability and access to routine vaccines in low income countries [18]. Zambia was one of 76 
the countries approved for GAVI support, although at present the HPV vaccine does not 77 
appear to be one of the inoculations subsidised by the GAVI alliance [19].  78 
  79 
Role of health professionals  80 
It is estimated that about 500 health workers were trained (and 50 clinics involved) in the 81 
HPV vaccination programme in Zambia [20]. As Zambia has a doctor-patient ratio of just 82 
0.173/1000 [21], and relatively few qualified gynaecologists – currently, there are only 40 83 
members of the Zambia Association of Gynaecologists and Obstetricians [22] – how health 84 
professionals interact with their female patients, and their role in delivering the HPV 85 
vaccination, is an important issue to consider [23]. Health professionals can significantly 86 
amplify HPV vaccine uptake, for example by recommending vaccination during routine 87 
doctor-patient consultations [24]. It has also been argued that the potential success of the 88 
HPV vaccination can be improved if the challenges faced by healthcare providers are 89 
understood [25]. 90 
Some research has explored HPV-related knowledge and attitudes amongst health 91 
professionals from developing countries, including African countries [26-28]. For example, a 92 
questionnaire-based study of 602 Nigerian healthcare professionals concluded that while they 93 
had good knowledge of HPV, their awareness the vaccine was low [26]. Nurses in particular 94 
had the lowest level of knowledge about the HPV vaccine, or even its existence. Another 95 
quantitative study conducted in a South African hospital reported similar findings [27]. Using 96 
self-report questionnaires administered to 345 nurses, this study attempted to determine the 97 
factors that affect recommendations of HPV vaccination to patients. They found that the 98 
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majority of the nurses lacked understanding of HPV infections and vaccinations, but yet were 99 
still willing to recommend vaccinations to patients. These findings mirror those of another 100 
questionnaire based study of 178 female nurses in Nigeria [28]. The South African study also 101 
found that nurses who thought their patients would accept HPV vaccination were more likely 102 
to recommend it [27]. The authors concluded that before a HPV vaccination programme 103 
could be successful nationwide, nurses needed to receive more education on HPV in general, 104 
as well as the HPV vaccination specifically. 105 
 106 
The present study 107 
Overall, past research has shown that exploring health professionals’ knowledge and views 108 
on HPV vaccination can yield valuable insights for vaccine implementation [27, 28]. Health 109 
workers’ perceptions can influence their administration of the HPV vaccine. For example, 110 
interviews with 15 health professionals in exploring their views on cervical cancer screening 111 
concluded that professionals’ perceptions of screening barriers influenced their management 112 
goals, practices and decisions surrounding how best to deal with cervical cancer [29]. Despite 113 
Zambia being particularly burdened by cervical cancer, and having recently benefited from a 114 
HPV vaccination pilot, no such study had been conducted in the region. The fact that Zambia 115 
has some of the highest cervical cancer mortality rates in the world emphasises the severity of 116 
the issue, and the requirement for health professional feedback on how to more effectively 117 
administer the HPV vaccination [4, 5, 30]. The views of health professionals involved in the 118 
HPV pilot scheme will be particularly helpful in identifying themes that may impede or 119 
facilitate vaccination rollout campaigns in this region. Thus, the current study aimed to 120 
address this gap in the literature, by exploring health professionals’ experiences of the HPV 121 
vaccination rollout in Zambia. 122 
 123 
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METHODOLOGY 124 
Thematic analysis was used as it allows the researcher to explore issues without the 125 
constraints that might otherwise be imposed by more structured analytical techniques, such as 126 
Interpretative Phenomenological Analysis (IPA) or GT [31]. A total of 15 healthcare 127 
professionals (4 males, 11 females) involved in cervical cancer were recruited from several 128 
health organisations in Kabwe, and also a private hospital/clinic, government hospital and 129 
district health center in Lusaka. Participants consisted of two gynaecologists, one oncologist, 130 
and twelve nurses. One professional worked in a private clinic, eight in a government 131 
hospital, one in a missionary hospital, one in a district health centre, two in an NGO hospice, 132 
and two at a cervical cancer clinic. The health worker (a nurse) from the district health centre 133 
was directly involved in running the pilot vaccination programme. Two professionals (nurses) 134 
working in Lusaka were parents/ guardians of girls targeted for vaccination. Given that there 135 
are only about 40 obstetrician/gynecologists in Zambia [22], finding anyone who knew about 136 
the HPV vaccine, or who worked on oncology wards, was a challenge. Health workers in 137 
charge of addressing cervical cancer found it hard to suggest who to talk to. 138 
A Dictaphone was used to record the (semi-structured) interviews. The device was an 139 
Olympus VN- 711PC with 2GB memory (circa 823 hours of recordings), battery life of up to 140 
72 hours, and USB connection for fast downloading to a PC. In order for the interviews to be 141 
standardized, each participant was asked the same ten core open-ended questions. These are 142 
presented in Table 1. Ethical approval was obtained from Liverpool John Moores University 143 
Research Ethics Committee (UREC), University of Zambia Biomedical Ethics Committee 144 
(UNZABREC, Ref. No. 004-06-15), and the Zambian Ministry of Health.  145 
Figure 1 illustrates the key procedural steps. One of the researchers travelled to 146 
Zambia to recruit participants. Purposive sampling (specifically snowball sampling) was 147 
used. Recruitment was implemented through third-party recommendations (friends, family 148 
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and acquaintances). Although an hour was allocated for each interview, on average, an 149 
interview lasted about 30 minutes. Participants were informed both in the consent form and 150 
verbally that they had the right to withdraw from the study at any given time. With 151 
gatekeeper’s approval, observation of some of the participants’ places of work was also 152 
conducted. Observation consisted of the researcher taking field notes on the surrounding 153 
facilities and the interactions between staff and patients. Overall data collection took 154 
approximately 3 weeks. 155 
Non-participant unstructured observation was conducted alongside the interviews to 156 
verify participants’ reports. Following data analysis, some of the participants were contacted 157 
via email. They were presented with an outline of the findings, and asked to provide 158 
feedback. As the mother of one of the researchers had passed away with cancer, we were 159 
aware this might introduce some personal bias during data analysis. Thus, an inductive 160 
approach was used in data coding, to ensure it was primarily data-driven. However, it is 161 
important to note that the coding of data is never conducted in an ‘epistemological vacuum’. 162 
Hence, the researchers acknowledged that the extent to which they were able to separate their 163 
subconscious thoughts from the analysis was limited [32]. 164 
…………………………………………… 165 
Insert Figure 1 here 166 
…………………………………………… 167 
…………………………………………… 168 
Insert Figure 2 here 169 
…………………………………………… 170 
…………………………………………… 171 
Insert Table 1 here 172 
…………………………………………… 173 
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…………………………………………… 174 
Insert Table 2 here 175 
…………………………………………… 176 
RESULTS 177 
Interview data was transcribed using the step-by-step procedure for thematic analysis 178 
outlined in the literature (see Figure 2) [31]. This process included generating initial codes 179 
(see Table 2), then searching for and reviving themes. A total of five overarching themes 180 
were derived from the data; ‘medical misconceptions’, ‘fear of the unknown’, ‘prior 181 
desensitisation’, ‘rural-urban divide’, and ‘economic concerns’. 182 
 183 
Theme 1: Medical misconceptions 184 
Despite the high-profile launch of the HPV vaccine roll-out in Zambia [15], participants 185 
expressed misconceptions and myths surrounding the vaccine which translated into a fear of 186 
the HPV vaccine in the community. Some of these misconceptions were that the vaccine 187 
causes infertility, illness such as cervical cancer itself, and that it is untested and Zambians 188 
are being used as experimental trials. Interestingly, one of the healthcare workers also held 189 
this belief: 190 
 191 
"What I have heard about the vaccine, some say that it has been developed to 192 
reduce the population, to reduce the fertility in a woman, an African woman." 193 
Participant J (L: 88-89) 194 
 195 
"They were saying if they give those vaccines to young girls, maybe those young 196 
girls they won’t get pregnant in the future, it will prevent them from getting 197 
pregnant, so those are beliefs that they have." Participant F (L: 16-18) 198 
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 199 
Theme 2: Fear of the unknown 200 
It appears that health workers not directly facilitating the pilot programme were not given 201 
HPV vaccine training [20]. Thus suggesting that the informing of the healthcare workers on 202 
the vaccine was neither nationwide nor continuous. While most participants were in support 203 
of the vaccine, some had fears of the side effects and felt that not enough research had been 204 
done on it. This lack of knowledge even led to open rejection of the vaccine for one 205 
participant: 206 
 207 
“I am telling you, about this vaccination, me I am against about it.” Participant D 208 
(L: 3) 209 
 210 
In addition, although parents were meant to have been given information on the vaccine by 211 
the teachers or nurses that visited the schools [15], it was apparent that this was not always 212 
the case. For some of the nurses, this lack of information affected their preparedness to allow 213 
their child to be vaccinated or recommend it to the community. 214 
 215 
 “I feel they haven’t done much work on it for them to even start giving a vaccine. 216 
And this is why I wasn’t comfortable for my daughter to have the vaccine.” 217 
Participant I (L: 2-8) 218 
 219 
“The females what they think about it, the others think that it is the wrong thing, 220 
they are scared, others they accept, but most of them they are scared. When the 221 
children tell their parents they want to give us this vaccine, most of the parents they 222 
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were refusing saying ‘no us we don’t know about this drug’, so they refuse.”  223 
Participant M (L: 19-22) 224 
 225 
Participants noted a lack of information on the HPV vaccine, contributing to the illusion not 226 
much research has been done on it. This perceived knowledge deficit seemed to affect their 227 
ability to deliver accurate vaccine information, and willingness to discuss the vaccine with 228 
patients, and the community. It appears professionals in Kabwe were not given such 229 
information as the pilot was carried out in the Lusaka district alone. However, even 230 
participants from Lusaka reported that information had not been disseminated specifically to 231 
them. 232 
 233 
Theme 3: Prior desensitisation  234 
Participants highlighted a need for specific cultural barriers to be addressed prior to rollout, to 235 
make the whole community (including health professionals) more receptive to the vaccine. 236 
This need for preliminary desensitisation was due to the cultural issues that were discussed, 237 
such as females’ reliance on male or elder’s permission to vaccinate their children. During 238 
the pilot children were sent home with consent slips, and parents were asked to sign them. 239 
Obtaining consent may be problematic if significant males or elders are not educated on the 240 
vaccine. Some participants felt that they have less influence over their patients than the males 241 
or elders in the society. 242 
 243 
“The cultural background, that a woman should seek permission from her 244 
husband, whether she should take her daughter for the vaccine. So those are 245 
cultural issues that will always be there.” Participant K (L: 155-158) 246 
 247 
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“But with education we should include the male folk because mostly we side line 248 
them, because they also play an important role, because if them the male folk 249 
understand, it will be easy to encourage the wife or the mother to the child or the 250 
daughter, it will be very easy.” Participant J (L: 122-125) 251 
 252 
Theme 4: Rural-urban divide 253 
Participants perceived differences between the rural and urban communities in terms of 254 
education levels. This lack of education in the rural communities in turn was perceived to 255 
create challenges in delivering health education, and getting them to understand the need for 256 
vaccinations. 257 
 258 
“When you speak to people with less education, or low education, they really 259 
don’t understand why it is important. They even don’t understand what it means 260 
to have cancer in the uterus and why the uterus is important. Or what it means to 261 
have cancer. Because it is just lack of knowledge, lack of education.” Participant 262 
G (L: 82-89) 263 
 264 
Theme 5: Economic concerns 265 
The cost of the HPV vaccine was seen to be a barrier to vaccination for most of the Zambian 266 
population. Participants stressed that if introduced in Zambia, the vaccine needs to be offered 267 
for free, or at a reduced cost. It was also noted that the availability and promotion of the 268 
vaccine would need to be sustained, especially as it is a multi-dosed vaccine. Issues regarding 269 
access to the vaccine were also highlighted, especially by professionals located far away from 270 
participating schools or health centres (e.g. cost of transport).   271 
 272 
12 
 
 “Because money is hard to come by in the current situation that there is, money 273 
is very difficult to come by, and there are only a few in formal employment, a 274 
large group they don’t have anything to do. So they can’t even be willing to spare 275 
that pin (ZMK 1) on a vaccine, they would rather spend that on food.” Participant 276 
L (L: 48-51) 277 
 278 
DISCUSSION 279 
The main findings can be summarised as follows: (a) HPV vaccine education is needed for 280 
health professionals; (b) concerns about unknown side effects and insufficient research may 281 
dampen uptake; (c) resolving cultural hindrances prior to vaccine rollout is essential; (d) 282 
increasing HPV education levels in rural communities is necessary, and (d) economic issues 283 
need to be addressed. The implication that rural populations are especially vulnerable to low 284 
HPV vaccination uptake (due to lack of education, and access to health care), and that the 285 
cost of the vaccine is a major barrier, is consistent with past research [33].  286 
 Even with the support of organisations like GAVI’s support, access to the 287 
vaccine remains a problem. However, economic barriers highlighted by participants were 288 
focused primarily on the cost of service users accessing the vaccine, rather than its delivery. 289 
Given that Zambia has a per capita income of about $1,700, and 70% of the population live 290 
below in poverty, many women may be unable to afford the cost of transportation to distant 291 
participating schools or health centres [20]. Possible solutions include local training 292 
programmes for doctors and nurses in remote areas, village-based screening, and use of 293 
mobile hospitals [20].  294 
 Various studies have highlighted the need for improved HPV awareness in less 295 
economically developed countries [10, 11, 34]. Medical knowledge may affect the support 296 
provided by some health professionals [35, 36], but not others [27]. This seems to suggest the 297 
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relationship between knowledge of the vaccine and support for its rollout locally is complex. 298 
Health professionals attitudes are informed by factors beyond medical knowledge, such as 299 
past vaccination experiences [26]. Of particular interest here was the scepticism in the 300 
vaccine’s safety and efficacy, despite the high profile launch of the vaccination programme 301 
[15]. Scepticism may discourage some health professionals from supporting its rollout [36]. 302 
Lack of information on the vaccine influenced beliefs in its safety, as well as willingness to 303 
recommend or discussed it with patients, correlating with past research [35]. Overall, the 304 
medical knowledge of some health professionals was a problem. Thus, it may be essential 305 
that health workers in this part of the world (including those not directly involved in 306 
administering the vaccine) are made aware that the HPV vaccine’s safety has been approved 307 
by relevant international health authorities, and that there is published supporting evidence 308 
[37]. Even so, merely presenting existing research may not be sufficient ‘proof’ of the 309 
vaccine’s safety for some. Apart from lack of vaccine literacy, there are some health 310 
professionals who will remain weary of the vaccine, due to the lack of longitudinal studies 311 
indicating its long-term effects [38]. Although this concern is understandable, as mentioned 312 
before, in countries so burdened by cervical cancer the rewards of a vaccine arguably 313 
outweigh the risks for the time being. 314 
Other studies have highlight various cultural hindrances to vaccination rollouts in 315 
developing countries, based on health professional feedback [26-28]. However, the present 316 
emphasis on the authoritative control Zambian men have over women’s health decision 317 
making (e.g. screening and vaccination) is unique to this study. This finding offers a unique 318 
insight into culture-specific barriers to the HPV vaccine in Zambia. Health professionals may 319 
be able to help address the issue, by using routine doctor-patient consultations, or local 320 
community outreach initiatives, to encouraging male patients to play a more constructive role 321 
in facilitating vaccination programmes. The misconception that the HPV vaccine causes 322 
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infertility is also a concern, seemingly associated with the gender-specific nature of HPV 323 
vaccination rollouts. Making the vaccine seem exclusive to women may fuel suspicions that it 324 
is being used as a form of population control by the government [39]. Thus, it may be helpful 325 
for health professionals to advise male patients to get vaccinated against HPV, as this has 326 
been shown to deflate such rumours [39]. Research suggests the general acceptability of the 327 
HPV vaccination in some African communities may be diminished by rumours, 328 
misunderstands, and fear about possible side effects (e.g., infertility), in addition to 329 
insufficient education about the vaccine [40]. To increase acceptance of the HPV vaccination 330 
in Zambia, health professionals need to find ways to educate local communities, not just 331 
about the importance of the HPV vaccination in cancer prevention, but also its role in the 332 
promotion of reproductive health (HPV infections are implicated in problematic reproductive 333 
functioning) [41].   334 
Overall, despite the introduction of the HPV vaccination programme in Zambia, 335 
health professionals involved in the rollout harbour multiple concerns that may diminish their 336 
willingness to support the scheme. Perhaps, most worryingly, some professionals (nurses, 337 
more so than doctors) have misconceptions about the vaccine that may denote deficits in 338 
medical training, and/or deeper socio-cultural factors transcending professional knowledge. 339 
These findings have implications for other developing countries, where knowledge of the 340 
HPV virus is inadequate, such as Sudan [10], and Lebanon [11]. Efforts to improve 341 
knowledge levels will have limited effectiveness if the health professionals responsible for 342 
running the necessary educational schemes are themselves poorly informed about the virus, 343 
and/or harbour misconceptions that discourage them from supporting vaccination 344 
programmes.  345 
Although research suggests widespread acceptance of HPV vaccine in Zambian 346 
women [12], the present findings nevertheless suggest a dire need for better understanding 347 
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amongst health workers of the role of the vaccine in advancing reproductive health. 348 
International organisations involved in vaccination rollout programmes (e.g., GAVI) should 349 
forge closer collaborative ties with Zambian (and other African) universities, to assist with 350 
developing new, or improving existing community educational programmes, to help correct 351 
rumours and misconceptions [18]. It is also necessary to identify and resolve cultural barriers 352 
around male authority, prior to offering the vaccination to female patients. While the present 353 
findings reflect experiences of health professionals, rather than the patients themselves, the 354 
key role played by the former in delivering vaccination services means their views can have a 355 
direct effect on patient outcomes [29]. Health professionals working in developing countries 356 
such as Zambia should recognise their own medical misapprehensions about HPV 357 
vaccination, and the reluctance of males and elders in local communities to support 358 
vaccination rollouts.   359 
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